Protara Therapeutics IncFRA Protara Stock Report

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2014-10-22. The firm is focused on identifying therapies for the treatment of cancer and rare diseases. The firm's pipeline includes TARA-002 and IV Choline Chloride. The firm's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).